Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Apr 15;9(4):e93953. doi: 10.1371/journal.pone.0093953. eCollection 2014.

A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.

Author information

  • 1Mycobacteria Research Laboratories, Department Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America.
  • 2Department of Chemistry, Stony Brook University, Stony Brook, New York, United States of America.
  • 3Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, New York, United States of America.
  • 4Infectious Disease Therapeutic Strategic Unit, Sanofi-Aventis R&D, Toulouse, France.
  • 5Infectious Disease Therapeutic Strategic Unit, Sanofi-Aventis R&D, Montpellier, France.
  • 6Department of Chemistry, Stony Brook University, Stony Brook, New York, United States of America; Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, New York, United States of America.

Abstract

Trisubstituted benzimidazoles have demonstrated potency against Gram-positive and Gram-negative bacterial pathogens. Previously, a library of novel trisubstituted benzimidazoles was constructed for high throughput screening, and compounds were identified that exhibited potency against M. tuberculosis H37Rv and clinical isolates, and were not toxic to Vero cells. A new series of 2-cyclohexyl-5-acylamino-6-N, N-dimethylaminobenzimidazoles derivatives has been developed based on SAR studies. Screening identified compounds with potency against M. tuberculosis. A lead compound from this series, SB-P17G-A20, was discovered to have an MIC of 0.16 µg/mL and demonstrated efficacy in the TB murine acute model of infection based on the reduction of bacterial load in the lungs and spleen by 1.73 ± 0.24 Log10 CFU and 2.68 ± Log10 CFU, respectively, when delivered at 50 mg/kg by intraperitoneal injection (IP) twice daily (bid). The activity of SB-P17G-A20 was determined to be concentration dependent and to have excellent stability in mouse and human plasma, and liver microsomes. Together, these studies demonstrate that SB-P17G-A20 has potency against M. tuberculosis clinical strains with varying susceptibility and efficacy in animal models of infection, and that trisubstituted benzimidazoles continue to be a platform for the development of novel inhibitors with efficacy.

PMID:
24736743
[PubMed - indexed for MEDLINE]
PMCID:
PMC3988029
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk